Tumor Xenograft Models

The tumor xenograft model (CDX) stands as a cornerstone in assessing the efficacy and safety of new drug treatments. LeadQuest Biotech offers a robust cell bank, providing timely and tailored CDX models to evaluate drug effectiveness across various tumors, including lungs, liver, and brain.

 

CDX Model

Our CDX model facilitates the study of prevalent tumor types like colorectal and breast cancer. By assessing drug efficacy and safety in vivo, scientists can expedite drug development processes. Moreover, it aids in unraveling tumor biology, treatment resistance mechanisms, and more.

 

Engineered Cell Line CDX Model

Constructing point mutant cell line CDX models allows for precise evaluation of drug efficacy against specific targets in vivo. This approach supports the development of tailored diagnosis, treatment, and prevention strategies in precision medicine. Additionally, it sheds light on drug resistance mechanisms and tumor microenvironment dynamics, enhancing our understanding of tumor biology.

 

Orthotopic Tumor Model

Our fluorescent cell-based orthotopic transplantation models offer insights into tumor growth and metastasis. Leveraging fluorescently labeled cells, these models enable the study of various aspects of tumor biology, including growth, metastasis, and treatment efficacy. Equipped with the IVIS Lumina III in vivo imaging system and cutting-edge model construction technologies, we swiftly construct fluorescent cell-based in vivo models for comprehensive drug efficacy evaluations.

 

CDX Model of Drug-resistant Strains

Drug-resistant cell line CDX models play a pivotal role in deciphering drug resistance mechanisms and developing effective anti-tumor therapies. By assessing drug efficacy against drug-resistant tumors and exploring molecular mechanisms of resistance, including gene expression alterations and signaling pathway changes, these models pave the way for more effective cancer treatments and improved patient outcomes.